Dear Friend of DKT,
We are pleased to share DKT’s 2023 Annual Report. This year’s report highlights DKT International’s impact and shares a bit about the way our affiliates (DKT WomanCare, Women First Digital, and carafem) work in tandem to ensure the ability of all individuals to determine their reproductive destinies. That work is under threat in many parts of the world, including this week in the USA where federal courts are again inserting themselves into issues that should be decided in the bedroom.
DKT is not deterred by these efforts to undermine choice. In 2022, DKT International’s work averted over 10.8 million unintended pregnancies, 9.3 million unsafe abortions, and 33,000 maternal deaths. DKT further delivered 61.6 million CYPs, which is a testament to the hard work undertaken around the world each day by more than 3,500 DKT team members. Our model places core responsibility, authority, and autonomy in the countries we serve – a long held principle that emphasizes local decision making. We also count on the generosity and trust of the many donors and supporters who make our work possible.
We continue to articulate our core values: treating people the right way, supporting an entrepreneurial spirit, focusing on results, reducing unnecessary bureaucracy, and building deep trust across the organization – all while having fun..
Speaking of fun, be sure to have a look at the Multi-Platform Engagement section in the report for a look back (and forward) at our global work across social media.
We welcome your feedback, ideas, and support as we look to the future and our 2030 goal of delivering 100 million CYPs and achieving 90% sustainability.
Sincerely,
Christopher Purdy
The numbers are in: DKT International expands overall impact in safe abortion in 2022
Our Annual Report is now available. Through the sale of contraceptive and safe abortion products, DKT International’s work averted over 10.8 million unintended pregnancies, 9.3 million unsafe abortions, and 33,000 maternal deaths in 2022. Specific to safe abortion, DKT International and DKT WomanCare Global averted over 9.3 unsafe abortions in 2022 through the sale of over 6 million medical abortion ‘combipacks’ (mifepristone + misoprostol), 23 million misoprostol tablets, 51K mifepristone only tablets, 310K MVA kits, and 2.2 million MVA cannulae.
For a breakdown of impact by country, visit our website to learn about more of DKT’s achievements in 2022.
DKT expands product portfolios in Honduras, Panama
Expansion into new markets and geographies increases product choice and contributes to the steady growth of DKT’s reach and impact. In 2022, DKT launched over 50 new products across 29 countries and our total CYPs grew 14% from 2021, reaching 61.6 million.
Already in 2023, DKT has continued expanding in Latin America by launching misoprostol, IUDs, and MVA kits in Honduras and condoms in Panama.
Conflicted rulings in the United States put medical abortion in limbo
Two federal courts issued contradictory rulings on April 7 regarding mifepristone, one of two drugs on the market in the United States prescribed for medical abortions. One ruling ends the FDA’s 20+ year old approval of the drug, banning mifepristone, and the other ruling bars the FDA from taking it off the shelves.
Vox Media reports that Matthew Kacsmaryk, a conservative federal district court judge in Texas, issued the long-awaited ruling, while Thomas Rice, a federal court judge in Washington state, issued a directly contradictory decision. DKT’s affiliate, carafem, has been front and center on this issue in the US media this week, assuring our domestic clients that carafem remains open for business and is ready to serve regardless of any outcome. Click here to keep up with the issue and with carafem in the news.
We’re on “the list” – DKT added to the “EC (Emergency Contraception) In the World” list
The European Consortium for Emergency Contraception’s (ECEC) ‘EC in the World’ list is a valuable tool widely used in the SRHR global community and DKT is proud to be amongst those included on this list. The database is a source of information on where EC is registered around the world, and whether it is available over-the-counter or by prescription.
To find out the status of EC in your country, visit the ECEC’s website.
New year, new partnerships: DKT and Rutgers extend and expand West Africa programs
DKT will continue its partnership with Rutgers – For sexual and reproductive health and rights for the ‘She Makes Her Safe Choice’ program, which further expands reproductive healthcare access in West Africa. The program has prevented over 4.8 million unsafe abortions, 13,000 maternal deaths, and 180,000 unintended pregnancies in Ethiopia, Kenya and West Africa since its inception in 2018. With continued support from the Nationale Postcode Loterij (Dutch Postcode Lottery) and the addition of a new partner, SheDecides, the program strengthens the work to reduce unsafe abortions and increase access to contraception in Burkina Faso, Togo, Benin, and Cameroon.
